Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05697640 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study to Investigate Improvement in Physical Function in SF-36 With Vericiguat Compared With Placebo in Participants With Post-COVID-19 Syndrome

StatusActive, Not Recruiting
PhasePhase 2
Started2023-06-22
View on ClinicalTrials.gov ↗
Record status
This record was last updated January 28, 2026 (before its estimated April 1, 2026 completion). Its status may not reflect the trial's current state.

Amendment history

2026-01-26
Recruiting→Active, Not Recruiting Study Status, Contacts/Locations, IPDSharing v3
Trial statusRecruiting→Active, Not Recruiting
Primary completion date2025-10-01→2026-04-01
Completion date2025-12-31→2026-12-31
Study sitesdetails revised at 1 of 1 site
2025-05-30
Study Identification, Study Status v2
Primary completion date2025-04-30→2025-10-01
Completion date2025-04-30→2025-12-31
Study titlerevised
Study to Investigate Improvement in Physical Function in SF-36 withWith Vericiguat Compared withWith Placebo in Participants withWith Post-COVID-19 Syndrome
2024-09-25
Not Yet Recruiting→Recruiting Study Identification, Study Status, Contacts/Locations, IPDSharing v1
Trial statusNot Yet Recruiting→Recruiting
Primary completion date2023-09→2025-04-30
Completion date2023-10→2025-04-30
Start dateestimated 2023-02→confirmed 2023-06-22
Study sitesdetails revised at 1 of 1 site
Study titlerevised
Study to Investigate Improvement in Physical Function in SF-36 Withwith Vericiguat Compared Withwith Placebo in Participants Withwith Post-COVID-19 Syndrome
2023-01-23
Original filing
The goal of this clinical trial is to evaluate the therapeutic value of an approved drug (Vericiguat) in patients with post-COVID-19 syndrome, who suffer from profound tiredness or fatigue, regardless of bed rest.The main questions it aims to answer are: • Does Vericiguat relieve fatigue and/or other symptoms associated with post-COVID-19 syndrome? • What are the side effects of Vericiguat in this patient population; and how common are they? Participants will be asked to participate for approx. 18 weeks. After screening, participants will receive assigned intervention of either 10 weeks of treatment with Vericiguat or matching placebo tablet, followed by 30 day follow-up period. Every participant will undergo trial, cardiovascular safety, and monitoring assessments. The results of this study will provide information on whether Vericiguat can alleviate PCS-related symptoms as well as insights into the pathophysiological processes of PCS, which in turn can help to develop therapies.
Trial Details
NCT Number NCT05697640
Lead Sponsor Charite University, Berlin, Germany
Collaborators: Bayer
Conditions Post-COVID ME/CFS
Enrollment 104 participants
Start Date 2023-06-22
Primary Completion 2026-04-01 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-01-28